“We welcome the Bill & Melinda Gates Foundation’s plans to establish a new nonprofit medical research institute to conduct integrated early-stage research and development (R&D) on key global health disease areas,” said Steve Davis, president and CEO of PATH.
“Given the many unmet needs in global health, we commend the Gates Foundation’s continued investment in early-stage R&D on vaccines, drugs, and diagnostics for urgent health priorities. We look forward to working together to accelerate the identification and development of new tools to address some of the world’s toughest health issues,” said Steve Davis.
“PATH has a rich history and robust portfolio of work on vaccines, drugs, and diagnostics. We appreciate the Gates Foundation’s continued support for PATH. We look forward to continued discussions with foundation leadership and staff, so that PATH’s efforts and expertise align with and complement the new institute’s work,” said Steve Davis.
PATH is the leader in global health innovation. An international nonprofit organization, we save lives and improve health, especially among women and children. We accelerate innovation across five platforms—vaccines, drugs, diagnostics, devices, and system and service innovations—that harness our entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, we take innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. Together, we deliver measurable results that disrupt the cycle of poor health. Learn more at www.path.org.
Posted April 25, 2017.